Investors / filer profile

Dambkowski Carl

Chief Medical Officer

active in 2 companies

Pro
Bought: Pro
Sold: 43
Filings: 2
Companies: 2026-08-05
Last filed

EDGAR · CIK 0001983476 ↗

Track record

How each disclosed position did against the S&P ~6 months later

No positions we can measure against the market yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$0.0000 bought · −$18.24M sold

All filings on record

Every Form 4 transaction we track for this filer


APGEApogee Therapeutics, Inc.	Sell $737.9K · 5,500 sh	2026-08-05	—
APGEApogee Therapeutics, Inc.	Exercise $94.3K · 4,125 sh	2026-08-05	—
APGEApogee Therapeutics, Inc.	Sell $730.1K · 5,500 sh	2026-07-01	—
APGEApogee Therapeutics, Inc.	Exercise $94.3K · 4,125 sh	2026-07-01	—
APGEApogee Therapeutics, Inc.	Sell $3.50M · 26,400 sh	2026-06-22	—
ORKAOruka Therapeutics, Inc.	Sell $882.2K · 12,583 sh	2026-06-12	—
ORKAOruka Therapeutics, Inc.	Sell $1.57M · 22,417 sh	2026-06-11	—
APGEApogee Therapeutics, Inc.	Sell $432.9K · 5,500 sh	2026-06-03	—
APGEApogee Therapeutics, Inc.	Exercise $94.3K · 4,125 sh	2026-06-03	—
ORKAOruka Therapeutics, Inc.	Sell $793.7K · 13,235 sh	2026-05-21	—

APGESell

2026-08-05 · Apogee Therapeutics, Inc.

$737.9K

—

APGEExercise

2026-08-05 · Apogee Therapeutics, Inc.

$94.3K

—

APGESell

2026-07-01 · Apogee Therapeutics, Inc.

$730.1K

—

APGEExercise

2026-07-01 · Apogee Therapeutics, Inc.

$94.3K

—

APGESell

2026-06-22 · Apogee Therapeutics, Inc.

$3.50M

—

ORKASell

2026-06-12 · Oruka Therapeutics, Inc.

$882.2K

—

ORKASell

2026-06-11 · Oruka Therapeutics, Inc.

$1.57M

—

APGESell

2026-06-03 · Apogee Therapeutics, Inc.

$432.9K

—

APGEExercise

2026-06-03 · Apogee Therapeutics, Inc.

$94.3K

—

ORKASell

2026-05-21 · Oruka Therapeutics, Inc.

$793.7K

—

Newest 10 of 43 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.